Obsidian Financial Communications Inc.
Thursday, June 7, 2012
Novo Nordisk A/S: FDA extends regulatory review period for insulin degludec and insulin degludec/insulin aspart by t...
http://ow.ly/1knrhZ
Newer Post
Older Post
Home